Accelerate Diagnostics Stock Analysis (NASDAQ:AXDX)

Add to My Stocks
$24.75 $0.25 (1%) AXDX stock closing price Apr 21, 2017 (Closing)
Watch Robo Advisor Video of AXDX Stock Analysis
Accelerate Diagnostics
Updated on : Apr 21, 2017
previous close
AXDX 24.8 (0%)
S&P 500 2348.7 (0%)
Closing Price On: Apr 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical Instruments
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-15.3%
Operating Profit
Operating Margin:
-27708.3%
Sector Average:
0.6%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Cash Flow
Operating cash flow:
-$12.8M
Net Income:
-$16.1M
PROS      CONS
Recent Growth
Long Term Growth
Operating Margins
Net Margins
ROIC
ROE
FCF Margin
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
AXDX PS :
5367.7
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-2924.6%
Return on Equity:
-63%
Free Cash Flow Margin:
-32250%
Double Tap To Exit Full Screen
0:00
/

Accelerate Diagnostics Analysis Video

134 5 2

View Accelerate Diagnostics stock analysis video. This is our AXDX analyst opinion covering the buy and sell arguments for AXDX stock.

Accelerate Diagnostics Inc Stock Rating (1.8/5)

Our Accelerate Diagnostics stock opinion is based on fundamentals of the company. This Accelerate Diagnostics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy AXDX stock?

  • The Year Over Year (YoY) revenue growth for Accelerate Diagnostics was 100% in 2016 Q4.

Should you sell AXDX stock?

  • Sales declined by -15.3% annually over the last 5 years.
  • Accelerate Diagnostics reported an average operating margin of -27708.3% over the Last Twelve Months (LTM).
  • Accelerate Diagnostics posted an average Net loss of -27658.3% in the last twelve months.
  • The company does not have profits. Hence the PE ratio is meaningless for AXDX stock.
  • The company is trading at a price to sales multiple of 5367.7, which is overvalued in comparison to the Medical Instruments industry average multiple of 4.6.
  • Accelerate Diagnostics's negative ROIC of -2924.6% indicates operational inefficiency.
  • Accelerate Diagnostics has a negative return on equity of -63%. This indicates that the firm is inefficient at generating profits.
  • Accelerate Diagnostics has a negative FCF (Free Cash Flow) margin of -32250%.

Comments on this video and Accelerate Diagnostics stock